Browsing: Diabetes Complications

Microvascular and macrovascular complications of diabetes: retinopathy, nephropathy, neuropathy, and cardiovascular risk.

All

DAPA-CKD demonstrated that dapagliflozin reduced the composite of a sustained 50% or greater eGFR decline, end-stage kidney disease, or renal or cardiovascular death by 39% in patients with albuminuric CKD with or without type 2 diabetes, extending nephroprotective SGLT2 inhibition beyond diabetic nephropathy to a broad CKD population for the first time.